Recombinant Human LAGE3 Protein，His

LAGE3 (L antigen family member 3) is a cancer/testis antigen that has garnered significant interest in cancer immunotherapy due to its restricted expression pattern in tumors and testicular tissues, making it a promising target for developing cancer vaccines and immunotherapeutic strategies. The expression of LAGE3 is often associated with various malignancies, including melanoma, lung cancer, and other solid tumors, which suggests that it could serve as a reliable biomarker for cancer diagnostics and prognostics. Research into LAGE3 has focused on understanding its role in tumor biology, particularly concerning its molecular functions and the mechanisms that regulate its expression in cancer cells. Additionally, studies have investigated the immunogenicity of LAGE3, exploring how it can be utilized to elicit robust immune responses against tumors. The potential of LAGE3 as a target for T-cell based therapies highlights the importance of identifying and characterizing LAGE3-derived peptides that can effectively bind to MHC molecules, activating cytotoxic T lymphocytes that specifically recognize and destroy LAGE3-expressing cancer cells. Overall, the exploration of LAGE3 as a therapeutic target represents a significant advancement in the field of cancer immunotherapy, providing opportunities for novel treatment approaches that could enhance the efficacy of existing therapies and improve patient outcomes.